[Congressional Bills 119th Congress]
[From the U.S. Government Publishing Office]
[S. 5237 Introduced in Senate (IS)]

<DOC>






119th CONGRESS
  2d Session
                                S. 5237

   To require the Director of the National Institute of Allergy and 
  Infectious Diseases to award a competitive grant for the Antibiotic 
Resistance Leadership Group for the purpose of facilitating a clinical 
   research network on antibiotic resistance, and for other purposes.


_______________________________________________________________________


                   IN THE SENATE OF THE UNITED STATES

                             August 4, 2026

  Ms. Hassan (for herself and Mr. Marshall) introduced the following 
  bill; which was read twice and referred to the Committee on Health, 
                     Education, Labor, and Pensions

_______________________________________________________________________

                                 A BILL


 
   To require the Director of the National Institute of Allergy and 
  Infectious Diseases to award a competitive grant for the Antibiotic 
Resistance Leadership Group for the purpose of facilitating a clinical 
   research network on antibiotic resistance, and for other purposes.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Stop Superbugs Act''.

SEC. 2. FUNDING FOR ANTIBIOTIC RESISTANCE CLINICAL RESEARCH.

    (a) In General.--The Director of the National Institute of Allergy 
and Infectious Diseases shall award a competitive grant for the 
Antibiotic Resistance Leadership Group for the purpose of facilitating 
a clinical research network on antibiotic resistance, which shall 
include focuses on--
            (1) supporting rapid recruitment of clinical trial 
        participants;
            (2) conducting clinical trial recruitment outreach in 
        community settings;
            (3) supporting the pairing of diagnostic and pharmaceutical 
        innovations during clinical trials; and
            (4) developing patient-reported outcomes in clinical 
        studies.
    (b) Authorization of Appropriations.--There is authorized to be 
appropriated to the Director of the National Institute of Allergy and 
Infectious Diseases such sums as may be necessary to carry out 
subsection (a).
                                 <all>